Company news: Roche

Share this article:
Roche reported disappointing third-quarter sales as key cancer drugs Avastin, Rituxan and Herceptin underperformed. Avastin sales declined 24% in the third quarter, while Herceptin was down 12% and Rituxan sales slid 10%. That, coupled with currency exchange effects, caused the company to miss analyst expectations and trumped an upbeat pipeline report from the firm.
Share this article:

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.